The FDA on October 18, 2017 granted regular approval to YESCARTA®, for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including Diffuse Large B-Cell Lymphoma (DLBCL) Not Otherwise Specified, Primary Mediastinal large B-cell Lymphoma, high-grade B-cell lymphoma, and DLBCL arising from Follicular lymphoma. YESCARTA® is a product of Kite Pharma, Inc.
Bottom Ad
Advertisement
Subscribe
